Experience
Valeant Pharmaceuticals International, Inc. v. Mylan Pharmaceuticals Inc.
Valeant Pharmaceuticals International, Inc.
Mylan Pharmaceuticals Inc.
Appellate counsel for Valeant and Salix, successfully argued motion to disqualify opposing counsel at Federal Circuit.
Valeant Pharmaceuticals International, Inc. v. Mylan Pharmaceuticals Inc., 18-2097, Fed. Cir., Judges Lourie, O'Malley, Reyna
Valeant Pharmaceuticals Int’l, Inc. v. Mylan Pharmaceuticals, Inc.
Valeant; Salix; Progenics
Valeant Pharmaceuticals NA, LLC v. Zydus Pharmaceuticals, Inc.
Valeant Pharmaceuticals NA, LLC
Mylan Pharmaceuticals Inc. v. Senju Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.; Bausch & Lomb Incorporated
Mylan Pharmaceuticals Inc. et al. v. Biogen MA Inc. et al.
Biogen MA Inc. et al.
Valeant Pharmaceuticals North America, LLC v. Actavis, Inc.
Valeant Pharmaceuticals North America, LLC
Finnegan secures 10 years of patent protection for Relistor®
Valeant; Salix; Progenics
Israel Bio-Engineering Project v. Amgen Inc., et al.
Amgen Inc., Immunex Corp.
Mylan Pharmaceuticals Inc. v. Bausch Health Ireland Ltd.
Bausch Health Ireland Ltd.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.